Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485012 · ClinicalTrials.gov registry record · Phase 1
Reinforcing Effects of Marijuana and Opioids
A Phase 1 study, sponsored by Shanna Babalonis, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05485012 is a Phase 1 study that has completed, run by Shanna Babalonis, PhD. The registered enrollment target is 8 participants.
The verdict
NCT05485012, a Phase 1 study, has completed, sponsored by Shanna Babalonis, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.
Interventions
- DRUG Opioid
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05485012
The ClinicalTrials.gov registry entry for NCT05485012 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanna Babalonis, PhD, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Opioid is the first listed.
NCT05485012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05485012 about?
NCT05485012 is a clinical study titled "Reinforcing Effects of Marijuana and Opioids". The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.
What is the current status of trial NCT05485012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-08-03. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT05485012?
The interventions under investigation include: Opioid (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT05485012?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.